Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1195 participants.

Also called NCT03888066

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,195 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03888066
  • EudraCT 2018-005030-38
Other papers using this trial's data
  • Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis JACC. Heart failure, 2024-12 DOI, PubMed 39340493
  • Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial European heart journal, 2022-11-01 DOI, PubMed 35900838, PMC9622299 In the PMC Open Access subset under CC BY-NC.
  • Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial American journal of nephrology, 2024 DOI, PubMed 39159624, PMC11651233 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Czechia, France, Georgia, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Russia, Serbia, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03888066. Randomized; quadruple masking; primary purpose prevention. Start 2019-04-24 (actual); primary completion 2021-09-02 (actual). Results posted on 2023-02-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
Acronym
DIAMOND
Condition
Hyperkalemia
Intervention (Drug)
Patiromer
Intervention (Drug)
Placebos
Lead sponsor
Vifor Pharma, Inc. (class: industry)
Collaborator
Syneos Health (class: other)

Record details

Record id
cardio:ct-nct03888066
Content hash
6f9c79fede9396559aa365dd3cc72e163dc9dc500f4f50b606a7d06ddea1a3e6